新辅助化疗在宫颈癌治疗中的应用及疗效观察

目的：探讨新辅助化疗联合手术治疗对宫颈癌的疗效。方法回顾性分析48例Ⅰb2～Ⅱb期宫颈鳞癌患者，分为研究组（新辅助化疗后行子宫切除术）和对照组（直接手术）。研究组行1～2个疗程新辅助化疗后，观察化疗前后癌灶的变化及手术切除的效果评价，并与对照组进行比较。结果新辅助化疗使肿瘤体积缩小或消失，有效率高达80．77％。研究组术后淋巴潴留囊肿及盆腔淋巴结转移率均低于对照组，两组比较差异有统计学意义（ P＜0．05）。所有入选患者3年总生存率为83．33％（研究组为84．62％，对照组为81．82％），两组患者术后生存率比较，差异无统计学意义（P＞0．05）。结论新辅助化疗可使肿瘤体积缩小或消失，扩大了手术适应证，降低术后并发症发生率。

Clinical observation of neoadjuvant chemotherapy for cervical cancer

Objective To investigate the clinical efficacy of neoadjuvant chemotherapy and surgery in the treat‐ment of cervical cancer .Methods 48 cases of Ⅰb2- Ⅱb cervical cancer patients were divided into two groups ：study group （neoadjuvant chemotherapy group） and control group （direct surgery group） .The study group was treated with 1-2 cycles of neoadjuvant chemotherapy to assess their efficacy of chemotherapy .Results After neoadjuvant chemotherapy tumor volume decreased and clinical efficiency was 80 .77% ,thereby reducing the clinical stage ,im‐prove the surgical resection rate ,expand the indications for surgery ,while surgery treatment could improve the qual‐ity of life of young patients with cervical cancer .Conclusion Neoadjuvant chemotherapy could decrease tumor volume after chemotherapy ,expand the indications for surgery ,and reduce the incidence of postoperative complications .